Trials / Conditions / Pulmonary Alveolar Proteinosis

Pulmonary Alveolar Proteinosis

14 registered clinical trials studyying Pulmonary Alveolar Proteinosis — 3 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Local Spraying of GM-CSF Via Bronchoscopy in the Treatment of Autoimmune Pulmonary Alveolar Proteinosis NCT06989333	Jiuwu Bai	Phase 2
Unknown	Prevalence of Adenosine Deaminase (ADA) Enzyme Deficiency Disease in Adult Patients With Pulmonary Alveolar Pr NCT05300360	TRPHARM	—
Unknown	Use of cSVF Via IV Deployment for Residual Lung Damage After Symptomatic COVID-19 Infection NCT04326036	Black Tie Medical, Inc.	EARLY_Phase 1
Completed	Updated Severity and Prognosis Score of Pulmonary Alveolar Proteinosis NCT04516577	Shanghai Pulmonary Hospital, Shanghai, China	—
Completed	Administration of Methionine in Patients With Pulmonary Alveolar Proteinosis by Mutation of the MARS Gene. NCT03887169	Assistance Publique - Hôpitaux de Paris	Phase 1 / Phase 2
Unknown	Sequential Therapy With WLL/Inhaling GM-CSF for Autoimmune Pulmonary Alveolar Proteinosis NCT03316651	Dai Huaping	Phase 2
Completed	Inhaled Molgramostim (rhGM-CSF) in Healthy Adult Subjects NCT02468908	Savara Inc.	Phase 1
Recruiting	A National Registry For Pulmonary Alveolar Proteinosis NCT02461615	Children's Hospital Medical Center, Cincinnati	—
Recruiting	European Management Platform for Childhood Interstitial Lung Diseases - chILD-EU Register and Biobank NCT02852928	Matthias Griese	—
Completed	Evaluation and Treatment Planning of Patients With PAP Using Thrive Ultra Short Echo Time MRI and CT NCT02081092	Children's Hospital Medical Center, Cincinnati	—
Unknown	Study of Subcutaneous Injection of Low-dose rhGM-CSF +/- WLL in PAP. NCT01983657	Shanghai Pulmonary Hospital, Shanghai, China	Phase 2
Completed	Multicenter International Cross-Sectional Evaluation of Pulmonary Alveolar Proteinosis Trial NCT03007134	Children's Hospital Medical Center, Cincinnati	—
Completed	Prospective Trial of Rituximab for Primary Pulmonary Alveolar Proteinosis NCT00552461	East Carolina University	Phase 2
Terminated	GM-CSF in Patients With Pulmonary Alveolar Proteinosis NCT00030056	The Cleveland Clinic	Phase 2